General Information of Drug (ID: DMVUW8A)

Drug Name
AVI-6002 Drug Info
Synonyms
NeuGene Plus (Ebola virus), AVI; Neugene (Ebola virus), AVI BioPharma; Polymerase cofactor VP35 modulator (Ebola virus infection,TSO), AVI BioPharma; Viral membrane associated protein VP24 modulator (Ebola virus infection, TSO), AVI BioPharma; AVI-4537 + AVI-4538 + AVI-4539 (Ebola virus infection), AVI BioPharma
Indication
Disease Entry ICD 11 Status REF
Ebola virus infection 1D60.0 Phase 1 [1]
Cross-matching ID
TTD Drug ID
DMVUW8A

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
AVI-6003 DMIJSDO Marburg virus infection 1D60.1 Phase 1 [2]
Drug Name Drug ID Indication ICD 11 Highest Status REF
AVI-6003 DMIJSDO Marburg virus infection 1D60.1 Phase 1 [2]
AVI-7537 DMLI9U6 Ebola virus infection 1D60.0 Phase 1 [2]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Ebola virus VP24 messenger RNA (EV VP24 mRNA) TTDJLWQ VP24_EBOSU Modulator [2]
Ebola virus VP35 messenger RNA (EV VP35 mRNA) TT3Z102 VP35_EBOSU Modulator [2]

References

1 ClinicalTrials.gov (NCT01353027) Safety Study of Single Administration Post-Exposure Prophylaxis Treatment for Ebola Virus. U.S. National Institutes of Health.
2 Discovery and Early Development of AVI-7537 and AVI-7288 for the Treatment of Ebola Virus and Marburg Virus Infections. Viruses. 2012 November; 4(11): 2806-2830.